Asset profile
Olvimulogene nanivacirepvec
Other
Evidence outlook · registrational
Ovarian Cancer: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2026-12.
Also in development:Non-Small Cell Lung Cancer · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
80 competitors in this universe: 5 direct rivals (same mechanism and indication), 3 same-class, 72 same-indication; 62 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Olvimulogene Nanivacirepvec: this drug | Phase 3 | Oncolytic Virus | No discrete molecular target | ||
| LN-145 | Phase 2 | Cell therapy | No discrete molecular target | ||
| RP1 | Phase 2 | Biologic (subtype unspecified) | No discrete molecular target | ||
| KB707 | Phase 1/2 | Gene therapy / editing | No discrete molecular target | ||
| SL-28 | Phase 1/2 | Biologic (subtype unspecified) | No discrete molecular target | ||
| KB-GDT-01 | Phase 1 | Biologic (subtype unspecified) | No discrete molecular target | ||
| ALF201 | Phase 2 | Cell therapy | No discrete molecular target | ||
| Adipose-Derived MSC Clusters (S.Biomedics) | Phase 1/2 | Cell therapy | No discrete molecular target | ||
| BGC101 | Phase 1/2 | Cell therapy | No discrete molecular target | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| Avutometinib | Approved | Small molecule | RAF/MEK, MEK1/2 and RAF (CRAF, BRAF) | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A |
…and 65 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (2)
2027 (1)
February 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.